Neonc Technologies Holdings, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- NEONC Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company that develops proprietary, patented platform technologies to transport therapeutics across the blood-brain barrier for treating brain cancers and central nervous system (CNS) diseases; its lead candidates include NEO100, a purified perillyl alcohol formulation in Phase IIa clinical trials for recurrent glioblastoma with FDA Orphan Drug and Fast Track designations, NEO212, a conjugate of temozolomide and perillyl alcohol in Phase I/II trials for primary and secondary brain tumors via oral administration, and the broader NEO platform supporting intranasal and transfemoral delivery methods for enhanced therapeutic efficacy in CNS malignancies such as grade 4 astrocytoma. The company targets oncology biopharmaceutical markets, focusing on glioblastoma and other intracranial tumors, with operations centered in the United States and plans for expansion into the MENA region. Founded in 2008 and headquartered in Calabasas, California, NEONC holds exclusive worldwide rights from USC to an intellectual property portfolio of 135 U.S. and international patents issued and pending, extending protections to 2038. Recent developments include the completion of an $18.5 million financing round in 2024 that valued the company post-money at approximately $220 million and advanced Phase II trials under FDA Fast Track status; a strategic acquisition of advanced AI and 3D bioprinting intellectual property; the appointment of Ishwar Puri to its Board of Directors; initiation of Cohort 3 enrollment in the Phase 1 trial of NEO212; board approval in June 2025 for a $50 million equity investment and MENA expansion via non-binding term sheet with Quazar Investment, including 1.4 million shares at $25 per share and a sub-license agreement with NuroCure; and receipt of the Breakthrough Medical Technology Achievement Award from the California Investment Forum.
Company News
NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger
NeOnc's Clinical Story Is Now the Main Event
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't
These Nasdaq Stories Are Heating Up
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
Breakout Stocks and Next Big Movers Could Be Taking Shape Now
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
Wall Street is Watching These Biotechs
NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212